Effects of Combination Lipid Therapy on Coronary Stenosis Progression and Clinical Cardiovascular Events in Coronary Disease Patients With Metabolic Syndrome: A Combined Analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS)

This publication has 21 references indexed in Scilit:

• Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
  JAMA, 2007
• Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials
  Current Opinion in Lipidology, 2006
• Benefits of Niacin in Patients With Versus Without the Metabolic Syndrome and Healed Myocardial Infarction (from the Coronary Drug Project)
  The American Journal of Cardiology, 2006
• Diagnosis and Management of the Metabolic Syndrome
  Circulation, 2005
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  JAMA, 2001
• The Metabolic Syndrome, LDL Particle Size, and Atherosclerosis
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2000
• Niacin Decreases Removal of High-Density Lipoprotein Apolipoprotein A-I But Not Cholesterol Ester by Hep G2 Cells
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1997
• Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.
  Heart, 1993
• Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B
  New England Journal of Medicine, 1990
• Implications of findings in the coronary drug project for secondary prevention trials in coronary heart disease. The coronary; drug project research group.
  Circulation, 1981